 |
| Alexander "Bo" Cumbo |
Stanton PR & Marketing represents the syndicate of high-powered life sciences investors that created AavantiBio, a gene therapy company focused on patients with rare genetic disorders.
Bain Capital Life Sciences, Perceptive Advisors, RA Capital Management and Sarepta Therapeutics put together $107M in Series A financing to launch AavantiBio.
Alexander “Bo” Cumbo, who served as chief commercial officer and executive VP at Sarepta, will helm AavantiBio, which is headquartered in the Boston area.
“Bo Cumbo has built a first-in-class rare disease commercial organization and has made tremendous contributions to Sarepta," said Doug Ingram, CEO. “We look forward to continuing to work with Bo as he builds a strong AavantiBio team and advances therapies to treat FA and other rare diseases.”
Stanton’s Scott Lessne handles AavantiBio.
FGS Global represents private equity firm Thoma Bravo as it makes a $4.6B bid for Darktrace, a UK-based cybersecurity artificial intelligence firm.
Edelman handles Viking Holdings, the river and ocean luxury cruise line that plans to raise $1B via an IPO priced in the $21 to $25 per share range.
Teneo is handling the initial public offering of CVC Capital Partners, one of Europe’s largest private equity firms with nearly $200B in assets under management.
Brunswick Group represents Endeavor Group Holdings as it agrees to go private via its acquisition by Silver Lake technology investment firm, which is handled by Edelman Smithfield.
Have a comment? Send it to 
No comments have been submitted for this story yet.